{"groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"FG000","title":"Part A: 1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"FG001","title":"Part A: 2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"FG002","title":"Part A: 4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"FG003","title":"Part A: 8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"FG004","title":"Part A: Placebo"},{"description":"Participants on background methotrexate therapy who were administered 1 x 1-mg LY3009104 capsule +1 identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg LY3009104 and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"FG005","title":"Part:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104)"},{"description":"Participants on background methotrexate therapy who were administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"FG006","title":"Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30"},{"description":"Participants on background methotrexate therapy who were administered 1 x 4-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"FG007","title":"Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30"},{"description":"Participants on background methotrexate therapy who were administered 2 placebo capsules orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"FG008","title":"Part B: Placebo /4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy who were administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"FG009","title":"Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30"},{"description":"Participants on background methotrexate therapy who were administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"FG010","title":"Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300"},{"description":"Participants on background methotrexate therapy who were administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"FG011","title":"Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30"},{"description":"Participants on background methotrexate therapy who were administered 2 placebo capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"FG012","title":"Part B: Placebo / 8 mg Baricitinib (LY3009104)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"49"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"49"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"23"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"48"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Part A (Treatment Period)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"3"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"23"},{"groupId":"FG008","numSubjects":"24"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"24"},{"groupId":"FG012","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"23"},{"groupId":"FG008","numSubjects":"24"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"24"},{"comment":"1 participant discontinued prior to receiving study drug","groupId":"FG012","numSubjects":"23"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"18"},{"groupId":"FG008","numSubjects":"20"},{"groupId":"FG009","numSubjects":"8"},{"groupId":"FG010","numSubjects":"10"},{"groupId":"FG011","numSubjects":"18"},{"groupId":"FG012","numSubjects":"18"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Part B (Extension Period)"}],"preAssignmentDetails":"Participants on background methotrexate therapy were assigned to a dose of 1, 2, 4, 8 mg baricitinib (LY3009104) or placebo capsule once daily in a double blind manner for 12 weeks followed by single blind treatment of 4 mg or 8 mg baricitinib (LY3009104) tablet once daily for 52 weeks extension period."}